Hot Investor Mandate: Early-Stage Venture Fund Invests in Novel Therapeutics Companies in Oncology and Autoimmune Diseases, Invests Primarily in Western Europe

10 Mar

An active early stage venture fund based in Western Europe has a team composed of experienced professionals in funding, entrepreneurship and therapeutic development. The firm has historically invested in computational biology, next generation tools for protein analysis and cell and gene therapy manufacturing technologies. Majority of technologies in the firm’s portfolio are relating to oncology, but going ahead the firm will consider any indication, if they find technology compelling. The firm has invested primarily in the UK and is willing to consider companies based in the broader Europe and in Switzerland in particular.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies that need local manufacturing, cancer vaccines, precision oncology medicine and novel therapies for autoimmune diseases. The firm is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, the firm is also interested in the investment in the existing companies, syndicating with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: